PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more
PharmaEngine (4162) - Total Liabilities
Latest total liabilities as of September 2025: NT$112.86 Million TWD
Based on the latest financial reports, PharmaEngine (4162) has total liabilities worth NT$112.86 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PharmaEngine - Total Liabilities Trend (2009–2024)
This chart illustrates how PharmaEngine's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PharmaEngine Competitors by Total Liabilities
The table below lists competitors of PharmaEngine ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai KEN Tools Co Ltd
SHE:300126
|
China | CN¥215.56 Million |
|
JMT Network Services Public Company Limited
BK:JMT
|
Thailand | ฿10.00 Billion |
|
Goodluck India Limited
NSE:GOODLUCK
|
India | ₹13.41 Billion |
|
Healthco Healthcare and Wellness REIT
AU:HCW
|
Australia | AU$409.10 Million |
|
Cub Elecparts Inc
TW:2231
|
Taiwan | NT$6.45 Billion |
|
Mildef Crete
TWO:3213
|
Taiwan | NT$982.97 Million |
|
Liaoning Shidai Wanheng Co Ltd
SHG:600241
|
China | CN¥118.79 Million |
|
Greenlam Industries Limited
NSE:GREENLAM
|
India | ₹18.20 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down PharmaEngine's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 43.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmaEngine's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmaEngine (2009–2024)
The table below shows the annual total liabilities of PharmaEngine from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$448.01 Million | +392.29% |
| 2023-12-31 | NT$91.01 Million | -3.66% |
| 2022-12-31 | NT$94.47 Million | +7.71% |
| 2021-12-31 | NT$87.70 Million | -55.20% |
| 2020-12-31 | NT$195.78 Million | +22.06% |
| 2019-12-31 | NT$160.40 Million | +5.06% |
| 2018-12-31 | NT$152.67 Million | -23.63% |
| 2017-12-31 | NT$199.90 Million | +24.56% |
| 2016-12-31 | NT$160.48 Million | +102.09% |
| 2015-12-31 | NT$79.41 Million | +340.73% |
| 2014-12-31 | NT$18.02 Million | -30.44% |
| 2013-12-31 | NT$25.90 Million | +82.39% |
| 2012-12-31 | NT$14.20 Million | -8.90% |
| 2011-12-31 | NT$15.59 Million | +12.60% |
| 2010-12-31 | NT$13.85 Million | -54.60% |
| 2009-12-31 | NT$30.50 Million | -- |